MEDFORD, N.Y. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care ("POC") diagnostic testing, today announced that Mary Lake Polan , M.D., Ph.D., M.P.H., has been appointed to its Board of Directors. Dr.
MEDFORD, N.Y. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care diagnostic testing, today reported financial results for the second quarter ended June 30, 2018 . Recent Accomplishments & Highlights Achieved total revenue of $8.7 million ,
MEDFORD, N.Y. and GENEVA, July 28, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic testing, today announced a collaboration with the Foundation for Innovative New Diagnostics (FIND) to expedite the feasibility testing of a rapid
MEDFORD, N.Y. , July 26, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic testing, today announced the Company plans to participate in the upcoming Canaccord Genuity Growth Conference in Boston, MA.
MEDFORD, N.Y. , July 25, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic testing, announced today that it will release financial results for the second quarter 2018 after the close of trading on Wednesday, August 8 , 2018. The
MEDFORD, N.Y. , July 19, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic testing, today announced the appointment of Christine M. Rousseau , Ph.D. as Vice President, Corporate Development, effective immediately.
MEDFORD, N.Y. , May 24, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic tests for infectious diseases, today announced the signing of a long-term agreement with Bio-Manguinhos to commercialize Chembio's POC diagnostic tests for Dengue,
MEDFORD, N.Y. , May 22, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic tests for infectious diseases, today announced that it has entered a non-binding Memorandum of Understanding (“MOU”) with the Massachusetts General Hospital (“MGH”)
MEDFORD, N.Y. , May 16, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that John Potthoff , Ph.D., has been appointed to its Board of Directors. Dr.
MEDFORD, N.Y. , May 09, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic tests for infectious diseases, today reported financial results for the first quarter ended March 31, 2018 . Recent Accomplishments & Highlights Achieved total
Print Page